Sponsor or institution

Clinical trials and research at Alexion Pharmaceuticals, Inc.

• 20Clinical trials
• 32Countries

Newest trials

All recruiting trials (20)

• Ravulizumab for Generalized Myasthenia Gravis in Chinese Adults

  This trial tests ravulizumab in Chinese adults with generalized myasthenia gravis to see if it helps symptoms while checking safety and how the drug behaves in the body.

  Recruiting at 8 sites Phase 3 Alexion Pharmaceuticals, Inc. · Beijing and 9 other locations · NCT07596784

• Ravulizumab in Chinese adults with NMOSD

  This study tests ravulizumab in Chinese adults with NMOSD who are AQP4 antibody positive to see if it helps reduce relapses and is safe.

  Recruiting Phase 3 Alexion Pharmaceuticals, Inc. · Beijing and 9 other locations · NCT07557420

• Safety and how the body handles ALXN2230 in healthy adults

  This test gives single under-the-skin doses of ALXN2230 to healthy adults to see if the medicine is safe and how the body processes and responds to it.

  Recruiting Phase 1 Alexion Pharmaceuticals, Inc. · London · NCT07352423

• Ravulizumab for people with clinical aHUS

  This study will test whether ravulizumab raises platelet counts in people diagnosed with clinical atypical hemolytic uremic syndrome (aHUS), including those with certain infections (excluding pneumococcal and STEC), pregnancy/postpartum, recent kidney transplant, malignant hypertension, or autoimmune conditions.

  Recruiting at 3 sites Phase 4 Alexion Pharmaceuticals, Inc. · Bunkyō City and 11 other locations · NCT07308574

• Acoramidis to slow progression of transthyretin cardiac amyloidosis

  This trial will test whether acoramidis slows disease progression in people with transthyretin cardiac amyloidosis who are either newly starting treatment or switching from tafamidis.

  Recruiting at 2 sites Phase 4 Alexion Pharmaceuticals, Inc. · Bunkyō City and 15 other locations · NCT07306949

• Oral steroid tapering for adults with generalized myasthenia gravis on ravulizumab.

  This study will try a predefined prednisone taper to see if adults with generalized myasthenia gravis on ravulizumab can safely reduce their daily steroid dose.

  Recruiting Phase 4 Alexion Pharmaceuticals, Inc. · Chicago, Illinois and 11 other locations · NCT07221838

• ALXN2350 for adults with BAG3-related dilated cardiomyopathy

  This study will test whether a single IV infusion of ALXN2350 is safe and helps adults who have dilated cardiomyopathy caused by a BAG3 mutation.

  Recruiting at 11 sites Phase 1/2 Alexion Pharmaceuticals, Inc. · Birmingham, Alabama and 10 other locations · NCT07218887

• ALXN1920 for adults with primary membranous nephropathy

  This trial will test whether ALXN1920 reduces urine protein in adults with primary membranous nephropathy who are at high risk of progression compared with placebo.

  Recruiting at 35 sites Phase 2 Alexion Pharmaceuticals, Inc. · Loma Linda, California and 39 other locations · NCT07157787

• Dual-target CAR T therapy (CD19 and BCMA) for relapsed or refractory AL (light-chain) amyloidosis

  This trial will try AZD0120, a CAR T cell therapy that targets CD19 and BCMA, to see if it is safe and helps people with relapsed or refractory AL (light-chain) amyloidosis.

  Recruiting at 15 sites Phase 1/2 Alexion Pharmaceuticals, Inc. · Phoenix, Arizona and 17 other locations · NCT07081646

• Ravulizumab for children with IgA nephropathy or IgA vasculitis nephritis

  This trial will test whether intravenous ravulizumab is safe and changes disease markers in children aged 2 to under 18 with biopsy‑proven IgA nephropathy or IgA vasculitis nephritis.

  Recruiting at 13 sites Phase 3 Alexion Pharmaceuticals, Inc. · Palo Alto, California and 14 other locations · NCT07024563

• Early ravulizumab for anti‑AChR antibody–positive generalized myasthenia gravis

  This study tests whether starting ravulizumab early can improve daily muscle weakness and function for people with anti‑AChR antibody–positive generalized myasthenia gravis.

  Recruiting at 9 sites Alexion Pharmaceuticals, Inc. · Bergamo and 22 other locations · NCT06967480

• Evaluating Ravulizumab for Reducing Delayed Graft Function After Kidney Transplant

  This study is testing if a new drug called ravulizumab can help kidney transplant patients avoid delayed graft function and reduce the need for dialysis.

  Recruiting at 113 sites Phase 3 Alexion Pharmaceuticals, Inc. · Phoenix, Arizona and 129 other locations · NCT06830798

• Evaluating gefurulimab for treating pediatric patients with generalized myasthenia gravis

  This study is testing a new drug called gefurulimab to see if it can help children and teens with generalized myasthenia gravis feel better.

  Recruiting at 11 sites Phase 3 Alexion Pharmaceuticals, Inc. · Washington D.C., District of Columbia and 12 other locations · NCT06607627

• Evaluating Danicopan with Ravulizumab or Eculizumab for Pediatric PNH Patients

  This study is testing if adding danicopan to the current treatments of ravulizumab or eculizumab can help kids with PNH have better hemoglobin levels.

  Recruiting at 4 sites Phase 3 Alexion Pharmaceuticals, Inc. · Saskatoon, Saskatchewan and 3 other locations · NCT06449001

• Safety of Ultomiris during pregnancy

  This study looks at how safe Ultomiris is for pregnant women and their babies to see if it causes any problems during pregnancy and breastfeeding.

  Recruiting at 4 sites Alexion Pharmaceuticals, Inc. · Boston, Massachusetts and 6 other locations · NCT06312644

• Registry of patients with AQP4+ NMOSD treated with C5 inhibitors

  This study is collecting information from people with AQP4+ NMOSD who are being treated with C5 inhibitors to see how well these treatments work and how they affect daily life over five years.

  Recruiting at 23 sites Alexion Pharmaceuticals, Inc. · Washington D.C., District of Columbia and 32 other locations · NCT05966467

• Observational study of pediatric hypophosphatasia patients receiving treatment

  This study is tracking kids with hypophosphatasia who are being treated with asfotase alfa to see how the treatment affects them over at least five years.

  Recruiting at 10 sites Alexion Pharmaceuticals, Inc. · Hartford, Connecticut and 11 other locations · NCT05234567

• Registry for patients with generalized myasthenia gravis treated with C5 inhibitors

  This study is collecting long-term information from people with generalized myasthenia gravis who are being treated with C5 inhibitors to see how well these treatments work and if they are safe.

  Recruiting at 51 sites Alexion Pharmaceuticals, Inc. · Birmingham, Alabama and 50 other locations · NCT04202341

• Registry for patients with Lysosomal Acid Lipase Deficiency

  This study is collecting information from people with Lysosomal Acid Lipase Deficiency to help improve their care and treatment.

  Recruiting at 104 sites Alexion Pharmaceuticals, Inc. · Phoenix, Arizona and 103 other locations · NCT01633489

• Registry for patients with Atypical Hemolytic-Uremic Syndrome

  This study is collecting information from people with Atypical Hemolytic-Uremic Syndrome to see how the disease progresses in those treated with eculizumab or ravulizumab and those who aren't treated at all.

  Recruiting at 118 sites Alexion Pharmaceuticals, Inc. · Aurora, Colorado and 140 other locations · NCT01522183

Quick answers

How many clinical trials run by Alexion Pharmaceuticals, Inc. are recruiting right now?

20, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 32 countries. The most sites are in United States (13 trials), Italy (11 trials), United Kingdom (9 trials), Japan (7 trials), Canada (7 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 6, Phase 4: 3, Phase 1/2: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →